Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT03546595 Active, not recruiting - Insulin Resistance Clinical Trials

Auricular Acupressure (AA) For Insulin Resistance in Women With Polycystic Ovary Syndrome

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

The present trial is a pilot study to investigate the effect of auricular acupressure on insulin resistance in women with PCOS.A total of 100 subjects will be enrolled into this study and will be randomized into two groups. Auricular acupressure or sham auricular acupressure will be treated for three months. The primary outcome is the whole body insulin action assessed with HOMA-IR.

NCT ID: NCT03515304 Active, not recruiting - Clinical trials for Acute Coronary Syndrome

Evolocumab in Acute Coronary Syndrome

EVACS
Start date: May 20, 2018
Phase: Phase 2
Study type: Interventional

Vascular and myocardial inflammation are significantly increased in Acute Coronary Syndrome (ACS) patients, are closely correlated to LDL-C levels, and are associated with these adverse consequences in the post-ACS patient population. Serum proprotein convertase subtilisin/kerin type 9 (PCSK9) levels are also increased in ACS, may raise LDL-C, and the investigators' pre-clinical studies indicate that PCSK9 is also a potent inducer of vascular inflammation. The addition of the PCSK9 antibody evolocumab, currently approved to lower LDL-C in certain patient populations, to current medical therapies would appear to be of particular benefit in an important subset of ACS patients, those with non-ST elevation myocardial infarction (NSTEMI) by markedly reducing LDL-C, stabilizing vulnerable plaque, and limiting inflammation-associated myocardial cell loss and resultant dysfunction.

NCT ID: NCT03503409 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Start date: May 14, 2019
Phase: Phase 2
Study type: Interventional

patients with MDS (Myelodysplastic Syndrome) and mutated IDH1 patients will be treated with AG120 (IDH1 inhibitor)

NCT ID: NCT03502668 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Start date: July 27, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic response in subjects with International Prognostic Scoring System (IPSS) risk category of low-risk or Intermediate-1 MDS. This study will be conducted in two phases. In phase 1 subjects will be randomized into 3 cohorts in a 28-day cycles. Phase 2, 80 new subjects will be randomized in a 1:1 ratio into 2 doses/schedules.

NCT ID: NCT03486626 Active, not recruiting - Clinical trials for Polycystic Ovary Syndrome

Endometrial Thickness and Subendometrial Vascularity in Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin

Start date: January 2, 2018
Phase: Phase 4
Study type: Interventional

The participants will receive metformin 500mg 3times per day for 3months and one month is left for spontaneous pregnancy to occur or not (primary outcome ) and the investigators will check endometrial thickness and subendometerial vascularity as markers of endometrial receptivity before and after the treatment.

NCT ID: NCT03467789 Active, not recruiting - Clinical trials for Basal Cell Carcinoma

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

Start date: October 1, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to study 50 patients with multiple Basal Cell Carcinoma (BCC) who will be receiving Photodynamic Therapy (PDT) as treatment for their tumors. This study wants to establish the optimal conditions for treating BCC tumors with PDT. Previous research suggests that taking Vitamin D prior to the start of PDT could help improve the effectiveness of the treatment in eliminating the BCC. Overall, this study will help establish oral Vitamin D3/PDT as a new combination therapy for skin cancer (BCC). Photodynamic Therapy (PDT) is an investigational (experimental) technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells. PDT is currently approved for the treatment of BCC in Europe, Canada, and Australia. However, it is experimental in the United States because it is not approved by the Food and Drug Administration (FDA).

NCT ID: NCT03462498 Active, not recruiting - Clinical trials for Coronary Artery Disease

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS

STOPDAPT-2 ACS
Start date: April 2, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS).

NCT ID: NCT03460483 Active, not recruiting - Clinical trials for Endometrial Carcinoma

Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care

OPTEC
Start date: March 30, 2018
Phase: N/A
Study type: Interventional

This clinical trial studies universal screening for deoxyribonucleic acid (DNA) mismatch repair deficiency in patients with endometrial cancer, mutations in the genes responsible for Lynch syndrome (inherited forms of endometrial cancers) and other DNA changes that could help guide treatment strategies. Universal tumor DNA sequencing may help doctors better understand how to personalize care, increase length of life, and increase quality of life in patients with endometrial cancer and their relatives.

NCT ID: NCT03436303 Active, not recruiting - Menopause Syndrome Clinical Trials

The Benefits and Risks of Different Menopausal Hormone Replacement Therapy Regimes in the Treatment of Menopause Syndrome

Start date: February 1, 2014
Phase: Phase 4
Study type: Interventional

A prospective, open‑label, randomized controlled clinical trial to compare the benefits and risks of half-dose or standard-dose conjugated equine estrogens(CEE) plus natural progesterone or dydrogesterone in menopausal hormone therapy .

NCT ID: NCT03432078 Active, not recruiting - Clinical trials for IBS - Irritable Bowel Syndrome

Individual vs. Group Hypnotherapy in Patients With Irritable Bowel Syndrome

Start date: August 15, 2011
Phase: N/A
Study type: Interventional

Patients' fulfilling Rome III criteria for IBS with symptoms refractory to standard treatment who are referred to a specialist unit for hypnotherapy are consecutively included in the study. The patients are randomized to either individual or group treatment given by a nurse trained in hypnotherapy. The treatment consists of eight sessions of gut directed hypno therapy during twelve weeks. Effects are measured by validated questionnaires at baseline and at various time points during the treatment period as well as after the completion of the treatment.